logo-loader

PreveCeutical Medical appoints two new board directors

Last updated: 12:15 21 Jun 2019 EDT, First published: 12:02 21 Jun 2019 EDT

board
PreveCeutical develops innovative options for preventive and curative therapies utilizing organic products

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) announced Friday the appointments of Keith Anderson and Mark Lotz to the company’s board of directors, effective immediately.

"Keith and Mark are experienced board members with extensive public sector experience and we are confident PreveCeutical will benefit from their insight, judgment and counsel,” said CEO Stephen Van Deventer. “Adding two independent directors with Keith and Mark's respective credentials further strengthens PreveCeutical's commitment to sound corporate governance practices."

Anderson, currently a senior officer of Syd Financial Inc and Boomer Financial Inc, has been in the Canadian capital markets business for over 30 years and was an Investment Advisor with Canaccord Genuity Corp from 1987 to 2011.

He was a former director and officer of several mineral exploration and cannabis companies, including a former director of Global Vanadium Corp, Vangold Mining Corp, Alchemist Mining Incorporated and Liberty Leaf Holdings Ltd (CSE:LIB) (OTCMKTS:LIBFF) and former CEO Alexis Financial Inc.

READ: PreveCeutical Medical reports positive results from its dual gene therapy research program

Lotz is a Chartered Professional Accountant practicing publicly through his firm Lotz CPA Inc. and currently serves as a director of Ascent Industries Corp (CSE:ASNT)(OTCMKTS:PGTMF), Golden Raven Resources Ltd., Logan Resources Ltd (CVE:LGR), Teal Valley Health Inc (formerly Radiant Health Care Inc), Vodis Pharmaceuticals Inc and Golden Lake Exploration Inc.

PreveCeutical, based in Vancouver, is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20